Completed PHASE3 INTERVENTIONAL 3-arm NCT01150097

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient

Sponsor: Novartis Pharmaceuticals

Conditions Liver Transplant Recipient

Interventions Corticosteroids Everolimus (reduced tacrolimus) Everolimus (tacrolimus elimination) Tacrolimus (reduced tacrolimus) Tacrolimus (tacrolimus control) Tacrolimus (tacrolimus elimination)

Updated 9 times since 2017 Last updated: Oct 8, 2018 Started: Mar 31, 2010 Primary completion: May 3, 2013 Completion: May 3, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01150097, this PHASE3 trial focuses on Liver Transplant Recipient and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Dec 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Dec 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barakaldo, Spain , Barcelona, Spain , Bedford Park, Australia , Berlin, Germany , Bogotá, Colombia , Bordeaux, France , CABA, Argentina , Cali, Colombia , Camperdown, Australia , Chapel Hill, United States and 43 more locations